Skip to main content
SpringerLink
Log in

Nanotechnology in Pulmonary Disease

  • Living reference work entry
  • First Online:
Encyclopedia of Nanotechnology

Definition

Nanotechnology in pulmonary disease encompasses the potential human health risks from occupational, environmental, or consumer exposure to engineered nanomaterials as well as the therapeutic benefits of nanomaterials for drug delivery to treat pulmonary diseases, enhance medical imaging of lung diseases, or provide tissue engineering for regenerative medicine.

Introduction

Engineered nanomaterials (ENMs) are intentionally manufactured nanoparticles with at least one dimension <100 nm that can be mass produced with a high degree of conformity in size and shape. The risk of ENMs to human health, specifically pulmonary disease, is not yet known due to the relative infancy of the nanotechnology revolution. However, studies with rodents that show adverse pro-inflammatory, pro-fibrogenic, and carcinogenic effects suggest that at least some ENMs will pose a human health hazard. Also, the utility of ENMs for therapies aimed at the treatment of pulmonary diseases in an early stage of...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Bonner, J.C.: Mesenchymal cell survival in airway and interstitial pulmonary fibrosis. Fibrogenesis Tissue Repair 3, 15 (2010)

    Article  Google Scholar 

  2. Donaldson, K., Murphy, F., Schinwald, A., Duffin, R., Poland, C.A.: Identifying the pulmonary hazard of high aspect ratio nanoparticles to enable their safety-by-design. Nanomedicine (Lond.) 6(1), 143–156 (2011)

    Article  Google Scholar 

  3. Kelleher, P., Pacheco, K., Newman, L.S.: Inorganic dust pneumonias: the metal-related parenchymal disorders. Environ. Health Perspect. 108(Suppl 4), 685–696 (2000)

    Article  Google Scholar 

  4. Bonner, J.C.: Respiratory toxicity. In: Smart, R.C., Hodgson, E. (eds.) Molecular and Biochemical Toxicology, 4th edn, pp. 639–670. Wiley, Hoboken (2008)

    Chapter  Google Scholar 

  5. Thompson, E.A., Sayers, B.C., Glista-Baker, E.E., Shipkowski, K.A., Taylor, A.J., Bonner, J.C.: Innate immune responses to nanoparticle exposure in the lung. J. Environ. Immunol. Toxicol. 1(3), 150–156 (2013)

    Google Scholar 

  6. Ryman-Rasmussen, J.P., Andersen, M.E., Bonner, J.C.: Fate and effects of carbon nanotubes following inhalation. In: Donaldson, K., Poland, C.A., Duffin, R., Bonner, J. (eds.) The Toxicology of Carbon Nanotubes, pp. 118–133. Cambridge University Press, Cambridge (2012)

    Google Scholar 

  7. Glista-Baker, E.E., Taylor, A.J., Sayers, B.C., Thompson, E.A., Bonner, J.C.: Nickel nanoparticles cause exaggerated lung and airway remodeling in mice lacking the T-box transcription factor, TBX21 (T-bet). Part. Fibre Toxicol. 11, 7 (2014)

    Article  Google Scholar 

  8. Schins, R.P.F., Albrecht, C., Gerloff, K.: Genotoxicity of carbon nanotubes. In: Donaldson, K., Poland, C.A., Duffin, R., Bonner, J. (eds.) The Toxicology of Carbon Nanotubes, pp. 150–173. Cambridge University Press, Cambridge (2012)

    Google Scholar 

  9. Sargent, L.M., Reynolds, S.H., Castranova, V.: Potential pulmonary effects of engineered carbon nanotubes: in vitro genotoxic effects. Nanotoxicology 4, 396–408 (2010)

    Article  Google Scholar 

  10. De Jong, W.H., Borm, P.H.: Drug delivery and nanoparticles: applications and hazards. Int. J. Nanomedicine 3(2), 133–149 (2008)

    Article  Google Scholar 

  11. Thorley, A.J., Tetley, T.D.: New perspectives in nanomedicine. Pharmacol. Ther. 140(2), 176–185 (2013)

    Article  Google Scholar 

  12. Vij, N., Gorde, A.: Theranostic applications of nanotechnology in chronic obstructive lung diseases. In: Vij, N. (ed.) Pulmonary Nanomedicine: Diagnostics, Imaging, and Therapeutics, pp. 1–14. Pan Stanford Publishing, Boca Raton (2012)

    Chapter  Google Scholar 

  13. Prato, M., Kostarelos, K., Bianco, A.: Functionalized carbon nanotubes in drug design and discovery. Acc. Chem. Res. 41(1), 60–68 (2008)

    Article  Google Scholar 

  14. Bonner, J.C.: Carbon nanotubes as delivery systems for respiratory disease: do the dangers outweigh the potential benefits? Expert Rev. Respir. Med. 5(6), 779–787 (2011)

    Article  Google Scholar 

  15. Hirsch, C., Roesslein, M., Krug, H.F., Wick, P.: Nanomaterial cell interactions: are current in vitro tests reliable? Nanomedicine (Lond.) 6(5), 837–847 (2011)

    Article  Google Scholar 

  16. Kreyling, W.G., Hirn, S., Schleh, C.: Nanoparticles in the lung. Nat. Biotechnol. 28(12), 1275–1276 (2010)

    Article  Google Scholar 

  17. Chandolu, V., Dass, C.R.: Treatment of lung cancer using nanoparticle drug delivery systems. Curr. Drug Discov. Technol. 10(2), 170–176 (2013)

    Article  Google Scholar 

  18. Kuroda, S., Yokoyama, T., Tam, J.O., Scott, A.W., Ma, L.L., Shanker, M., Jin, J., Goerlich, C., Willcutts, D., Roth, J.A., Sokolov, K., Johnston, K.P., Ramesh, R.: Multifunctional tumor-targeted nanoparticles for lung cancer. In: Vij, N. (ed.) Pulmonary Nanomedicine: Diagnostics, Imaging, and Therapeutics, pp. 15–44. Pan Stanford Publishing, Boca Raton (2012)

    Chapter  Google Scholar 

  19. Mulvey, J.J., Villa, C.H., McDevitt, M.R., Escorcia, F.E., Casey, E., Scheinberg, D.A.: Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery. Nat. Nanotechnol. 8(10), 763–771 (2013)

    Article  Google Scholar 

  20. Chakravarty, P., Marches, R., Zimmerman, N.S., Swafford, A.D., Bajaj, P., Musselman, I.H., Pantano, P., Draper, R.K., Vitteta, P.S.: Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes. Proc. Natl. Acad. Sci. U. S. A. 105(25), 8697–8702 (2008)

    Article  Google Scholar 

  21. Mehanna, M.M., Mohyeldin, S.M., Elgindy, N.A.: Respirable nanocarriers as a promising strategy for antitubercular drug delivery. J. Control. Release 187C, 183–197 (2014)

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biological Sciences, North Carolina State University, Box 7633, 27695-7633, Raleigh, NC, USA

    James C. Bonner

Authors
  1. James C. Bonner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James C. Bonner .

Editor information

Editors and Affiliations

  1. Biomimetics (NLB²), Ohio State University Nanoprobe Lab. for Bio- & Nanotechnology, Columbus, Ohio, USA

    Bharat Bhushan

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media Dordrecht

About this entry

Cite this entry

Bonner, J.C. (2014). Nanotechnology in Pulmonary Disease. In: Bhushan, B. (eds) Encyclopedia of Nanotechnology. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6178-0_100904-1

Download citation

  • DOI: https://doi.org/10.1007/978-94-007-6178-0_100904-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Online ISBN: 978-94-007-6178-0

  • eBook Packages: Springer Reference Chemistry and Mat. ScienceReference Module Physical and Materials ScienceReference Module Chemistry, Materials and Physics

Publish with us

Policies and ethics

Search

Navigation